NCT04394195

sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 72 (actual)
• Sponsor: CHU de Reims · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Short description of the protocol intended for the lay public. Include a brief statement of the study hypothesis (Limit : 5000 characters) The management of critically-ill patients with organ failure due to COVID-19 represents a major healthcare burden. While endothelial inflammation has been reported in these patients, the pathophysiological mechanisms remain incompletely elucidated.

Detailed description

Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures. (Limit : 32 000 characters) The soluble fms-like tyrosine kinase 1 (SFlt1) is the soluble form of VEGF-A receptor 1 (VEGFR1). By linking VEGF-A with a high affinity, sFlt1 blocks the VEGF-A / VEFR1 axis and impairs endothelial homeostasis. Its production increases during inflammation. We hypothesize that sFlt1 is upregulated and correlates with endothelial dysfunction and outcomes in critically-ill patients with COVID-19.

Conditions

• CORONAVIRUS INFECTIONS

Interventions

Type	Name	Description
OTHER	measurement of circulating sFlt1 concentration	blood circulating sFlt1 concentration will be determined

Timeline

• Start date: 2020-04-03
• Primary completion: 2020-05-01
• Completion: 2020-09-01
• First posted: 2020-05-19
• Last updated: 2021-04-01

Locations

1 site across 1 country: France